CTI and ATI join fight against Covid-19

As the world’s scientists rush to find vaccines and therapeutics to treat Covid-19, there’s another group of scientists who are working just as hard to protect the drugs and safely deliver them to patients and fight counterfeiters.

‘Once a Covid-19 drug is produced, it needs to be safely distributed throughout the world and must survive the risks of freezing, heat abuse, sun and UV damage, tampering and counterfeiting,’ said Lyle Small, CTI’s chief executive officer. ‘The world is throwing money at beating the coronavirus in a compressed timeline. This just amplifies the risk and CTI has simple solutions for all of these related efficacy challenges.’

‘ATI is already working with dozens of pharmaceutical companies and we are diligently launching this program to support all of their Covid-19 R&D and launch efforts,’ added Randall Lane, chief executive officer of ATI.

CTI and ATI’s goals are to protect at least 100 million units of drugs being distributed to health care officials. The CTI donation has an equivalent value of USD 5 million.